InflaRx presents novel preclinical findings for INF904 at the 19th European Meeting on Complement in Human Disease Page 1

JENA, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) — InflaRx NV (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapies targeting the complement system, today announced the presentation of preclinical data for the company’s novel oral C5aR inhibitor, INF904, at the European Meeting on Complement in Human Diseases (EMCHD) 2024, being held September 2-6, 2024 in Lübeck, Germany.

Members of the InflaRx leadership also participated in a satellite symposium highlighting the role of the C5a/C5aR1 axis in driving inflammation and served as representatives from the biopharmaceutical industry on a panel focused on the relevance of targeting C3 and C5. InflaRx also hosted a lunchtime seminar focused on C5a/C5aR inhibition in human disease with best-in-class compounds.